Capital Research Global Investors
BIO icon

Capital Research Global Investors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Capital Research Global Investors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130M Buy
443,483
+57,904
+15% +$16.4M 0.02% 282
2026
Q1 		$107M Sell
385,579
-108,893
-22% -$31.4M 0.02% 302
2025
Q4 		$150M Buy
494,472
+76,117
+18% +$23.8M 0.03% 263
2025
Q3 		$117M Buy
+418,355
New +$114M 0.02% 284

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital Research Global Investors's BIO Position: Q2 2026 in Review

Capital Research Global Investors increased its Bio-Rad Laboratories Class A (BIO) stake by 15% in Q2 2026, buying an estimated $16.4M and bringing the position to 443,483 shares worth $130M. The position accounts for 0.02% of the portfolio, ranked #282.

Capital Research Global Investors first reported a position in BIO in Q3 2025 and has held it in 4 quarters since. The position peaked at $150M in Q4 2025. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Capital Research Global Investors held 443,483 shares of Bio-Rad Laboratories Class A worth $130M as of Q2 2026.
  • Capital Research Global Investors bought 57,904 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $16.4M.
  • Bio-Rad Laboratories Class A made up 0.02% of Capital Research Global Investors's portfolio in Q2 2026, its #282 holding.
  • Capital Research Global Investors first reported a position in Bio-Rad Laboratories Class A in Q3 2025 and has held it in 4 quarters since.
  • Capital Research Global Investors's Bio-Rad Laboratories Class A position peaked at $150M in Q4 2025.
  • 399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Capital Research Global Investors's 13F filing for Q2 2026, filed 12 Aug 2026.